… When comparing our cohort of patients with LVEF ≤40% to the dapagliflozin arm in DAPA-HF…
our cohort of chronic HFrEF patients were eligible for dapagliflozin according to the DAPA-…

… DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; with dapagliflozin)
2,… of SGLT2 inhibitors to treat patients with heart failure with reduced ejection fraction (…

… of the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) trial,
we … In this post hoc analysis of DAPA-HF, we used previously described methods to enable …

… The primary end point in most heart failure (HF) trials is a composite of time to a first … We
examined the effects of dapagliflozin compared with placebo on a hierarchical composite …

… Characteristics for the patients in our population that were eligible for DAPA-HF and
EMPEROR-reduced compared to the cohorts receiving dapagliflozin and empagliflozin in respective …

… of dapagliflozin in HF were consistent across regions using individual patient data from >11,000
participants enrolled in 2 placebo-controlled randomized trials, DAPA-HF (Dapagliflozin …

… We were unable to determine with certainty whether dapagliflozin in patients with T2DM and
HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to …

… We examined whether the SGLT2 inhibitor dapagliflozin improved the degree of physical …
Kansas City Cardiomyopathy Questionnaire (KCCQ) in DAPA-HF. Hypothesis: Dapagliflozin, …

… the effect of dapagliflozin on symptomatic relief in those patients. … of patients with heart
failure treated with dapagliflozin experienced clinically meaningful improvements in heart failure-…

… In this large, contemporary, non-selective real-world HF population, we found that
eligibility for dapagliflozin and empagliflozin based on the eligibility criteria from the DAPA-HF, …